Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.42 |
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 3/20 | 0.40 | |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668369 | 0.86 | GRM5 (0.48) | GRM5GRM4GCKPDF | |
| SCHEMBL4114224 | 0.85 | GRM5 (0.50) | GRM5PDF | |
| SCHEMBL2668370 | 0.85 | GCK (0.44) | GRM5GRM4GCKAKT1PDF | |
| SCHEMBL4102212 | 0.83 | GRM5 (0.46) | GRM5GRM4GCKAKT1PDF | |
| SCHEMBL4102259 | 0.82 | AAK1 (0.48) | GRM5GRM4GCK | |
| SCHEMBL4114863 | 0.82 | GRM5 (0.42) | GRM5GRM4GCKPSEN1PSEN2 | |
| SCHEMBL2659105 | 0.73 | GCK (0.70) | GCK | |
| SCHEMBL2651453 | 0.73 | GCK (0.70) | GCK | |
| SCHEMBL2651196 | 0.73 | GCK (0.70) | GCK | |
| SCHEMBL4114293 | 0.72 | GRM5 (0.46) | GRM5GCKAKT1PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173645-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GRM5 2182/4885GRM4 2591/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.